Clinical trial
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
NCT00274313 · Parion Sciences, Industry · Completed
Key facts
| NCT number | NCT00274313 |
|---|---|
| Title | Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients |
| Official title | A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis |
| Lead sponsor | Parion Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | 552-02 |
| Enrollment | 40 |
| Start date | Jan 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jan 10, 2006 |
| Last update posted | Jan 14, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: